Lineage, Inc. (LINE) AI Stock Analysis

• Market Cap: $8.18B
• Dividend Yield: 5.8%
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 26,000
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Industrial
• EPS (TTM): -0.44
• Shares Outstanding: 228,289,630
• 10 Day Avg. Volume: 1,582,539
• 30 Day Avg. Volume: 1,277,986
• PEG Ratio: -0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 2.09
• P/FCF Ratio: 932.24
• Enterprise Value/Market Cap: 2.16
• Enterprise Value/Revenue: 3.29
• Enterprise Value/Gross Profit: 10.23
• Enterprise Value/Ebitda: 17.65
• 1Y Price Target: $40.57
• Price Target Upside: 13.26% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 15
• EPS Forecast (FY): -0.32
• Revenue Forecast (FY): $5.40B

• Rating: 48 Neutral
• Price Target: $33.00 ▼(-7.87% Downside)

Lineage, Inc. faces significant challenges with profitability and operational efficiency, as reflected in its financial performance score. The technical analysis indicates a bearish trend, further impacting the overall score. While the dividend yield is attractive, the negative P/E ratio and lowered earnings guidance weigh heavily on the stock's prospects. The earnings call provided some positive developments, but these were largely offset by concerns over future performance and increased interest expenses.

Positive Factors

Innovative Business Model

Lineage's focus on regenerative medicine and cellular therapies positions it well in a growing market, leveraging proprietary technologies for advanced treatments.

Strategic Partnerships

Strategic partnerships enhance Lineage's R&D capabilities and revenue streams through collaborations, licensing, and milestone payments, supporting long-term growth.

Record Adjusted EBITDA

Record adjusted EBITDA indicates strong operational performance and efficiency, supporting financial stability and potential for reinvestment in growth initiatives.

Negative Factors

Profitability Challenges

Negative net profit margin highlights ongoing profitability challenges, which could hinder reinvestment and long-term financial health if not addressed.

Lowered Guidance

Lowered guidance reflects anticipated operational challenges, potentially impacting investor confidence and the company's ability to meet financial targets.

Interest Expense Increase

Rising interest expenses could strain cash flow and limit financial flexibility, affecting Lineage's ability to fund growth and manage debt effectively.

Lineage, Inc. Business Overview & Revenue Model

Company Description

Lineage, Inc. (LINE) is a biotechnology company focused on developing innovative solutions in the field of regenerative medicine and cellular therapies. The company operates primarily in the healthcare sector, leveraging its proprietary technologies to produce and commercialize advanced therapies aimed at treating various diseases and conditions. Lineage's core products include stem cell-derived therapies and tissue engineering solutions, with a strong emphasis on applications for spinal cord injuries, retinal diseases, and other chronic conditions.

How the Company Makes Money

Lineage, Inc. generates revenue through multiple streams, including the commercialization of its stem cell therapies and partnerships with pharmaceutical and biotechnology companies for research and development collaborations. The company often enters into licensing agreements that allow it to earn royalties on sales of products developed using its proprietary technologies. Additionally, Lineage may receive milestone payments tied to the success of clinical trials and regulatory approvals of its therapies. Strategic partnerships with academic institutions and research organizations also play a crucial role in funding its development programs, further contributing to its revenue generation.

Lineage, Inc. Financial Statement Overview

Summary

Lineage, Inc. shows stable revenue and operational cash flow but faces challenges with profitability and free cash flow generation. The balance sheet is moderately leveraged with a reasonable equity position. The company needs to address operational inefficiencies and improve profitability to enhance its financial health.

Income Statement

Lineage, Inc. has shown stable revenue over the past year, with a slight decline from the previous year. The gross profit margin is healthy at approximately 33%, but the net profit margin is negative due to significant net losses. The EBIT and EBITDA margins indicate operational challenges, with EBIT being particularly low, suggesting high operating expenses or other costs impacting profitability.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced approach to financing. However, the return on equity is negative due to net losses, which is a concern for investors. The equity ratio is around 46%, showing a reasonable level of equity financing relative to total assets.

Cash Flow

Lineage, Inc. has a positive operating cash flow, which is a good sign of operational efficiency. However, free cash flow is minimal, indicating limited cash available after capital expenditures. The operating cash flow to net income ratio is strong, but the free cash flow to net income ratio is low, reflecting challenges in generating free cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement
Total Revenue	5.36B	5.34B	5.34B	4.93B	3.70B	517.82M
Gross Profit	1.72B	1.76B	1.75B	1.46B	1.13B	517.82M
EBITDA	999.00M	547.00M	1.24B	976.00M	632.90M	386.30M
Net Income	-177.00M	-664.00M	-77.00M	-63.00M	-153.30M	-140.67M
Balance Sheet
Total Assets	19.20B	18.66B	18.87B	18.56B	16.42B	2.75B
Cash, Cash Equivalents and Short-Term Investments	75.00M	173.00M	68.00M	170.60M	209.10M	89.06M
Total Debt	7.90B	6.88B	11.05B	10.69B	9.60B	1.03B
Total Liabilities	9.81B	8.97B	12.85B	12.45B	11.14B	1.25B
Stockholders Equity	8.38B	8.64B	5.05B	5.17B	4.34B	1.50B
Cash Flow
Free Cash Flow	135.00M	12.00M	30.00M	-312.00M	-359.20M	265.06M
Operating Cash Flow	654.00M	703.00M	796.00M	501.00M	329.90M	268.30M
Investing Cash Flow	-1.10B	-919.00M	-1.07B	-2.37B	-3.41B	-689.09M
Financing Cash Flow	118.00M	320.00M	136.00M	1.84B	3.03B	426.21M

Lineage, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 35.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LINE, the sentiment is Neutral. The current price of 35.82 is above the 20-day moving average (MA) of 35.01, below the 50-day MA of 37.82, and below the 200-day MA of 44.60, indicating a neutral trend. The MACD of -0.78 indicates Negative momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 85.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LINE.

Lineage, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EGP	78 Outperform	$9.63B	37.87	7.83%	3.17%	11.10%	-1.65%
REXR	77 Outperform	$9.69B	29.33	4.03%	4.10%	10.27%	15.25%
STAG	75 Outperform	$7.34B	30.35	7.17%	3.80%	9.62%	31.08%
TRNO	72 Outperform	$6.50B	20.03	8.38%	3.43%	21.13%	74.37%
FR	68 Neutral	$7.78B	31.89	8.97%	3.05%	9.66%	-23.17%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
LINE	48 Neutral	$8.18B	―	-2.06%	5.80%	―	―

Lineage, Inc. Corporate Events

Lineage, Inc. Reports Q3 2025 Financial Results

Lineage, Inc., the world’s largest global temperature-controlled warehouse REIT, operates over 485 facilities across North America, Europe, and Asia-Pacific, providing supply chain solutions for food and beverage producers, retailers, and distributors.

Lineage, Inc. Reports Mixed Sentiment in Earnings Call

The recent earnings call for Lineage, Inc. presented a mixed sentiment, reflecting both achievements and challenges. The company celebrated record adjusted EBITDA and significant growth in its Global Integrated Solutions segment, driven by strategic investments and productivity gains from the LinOS platform. However, these positive developments were tempered by lowered fourth-quarter guidance, difficulties in U.S. occupancy, and a decline in same warehouse NOI due to tariff uncertainties and competitive pressures. Additionally, an increase in forecasted interest expenses poses a future challenge for the company.

Lineage, Inc. Reports Q3 2025 Financial Results

On November 5, 2025, Lineage, Inc. reported its financial results for the third quarter of 2025, showing a 3.1% increase in total revenue to $1,377 million, despite a GAAP net loss of $112 million. The company experienced growth in Adjusted EBITDA and AFFO, but faced challenges due to tariff uncertainty and lower occupancy in the US. Consequently, Lineage adjusted its full-year 2025 guidance to the lower end of previous ranges, while expressing optimism about long-term prospects due to declining new supply deliveries and growing demand for frozen food.

The most recent analyst rating on (LINE) stock is a Hold with a $44.00 price target. To see the full list of analyst forecasts on Lineage, Inc. stock, see the LINE Stock Forecast page.

Lineage, Inc. Appoints New CFO and VP of Investor Relations

On October 17, 2025, Lineage, Inc. announced the appointment of Robb LeMasters as Chief Financial Officer, effective November 10, 2025, succeeding Robert Crisci who is retiring. LeMasters brings extensive experience from BWX Technologies and other financial firms, expected to drive growth and shareholder value. Additionally, Ki Bin Kim was appointed as Vice President of Investor Relations, bringing expertise from Truist Securities to strengthen investor relations and communicate the company’s strategic vision.

The most recent analyst rating on (LINE) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Lineage, Inc. stock, see the LINE Stock Forecast page.